The acquisition of Galzin® aligns with Eton Pharmaceuticals' strategic focus on rare diseases, potentially expanding its market reach and product offerings. This move is likely to positively impact Eton's stock price in the short term as it strengthens its position in the niche market of rare disease treatments.